💡 Suggest / Edit
← Wiki Index / Microbiology & Immunology / Immunogenic Cell Death
🦠 Microbiology & Immunology

Immunogenic Cell Death

Immunogenic cell death (ICD) is a regulated form of cell death in which stressed and dying cells emit spatiotemporal damage-associated molecular patterns (DAMPs) that activate dendritic cells and prime antigen-specific cytotoxic T-lymphocyte immunity.

10 min read • Updated October 2026 • Knowledge Wiki • AI-Assisted & Human-Supervised

Immunogenic cell death (ICD) is a functionally specialized modality of regulated cell death in immunology and oncology in which a dying mammalian cell—whether infected by an intracellular pathogen or killed by specific anti-cancer therapeutics—undergoes premortem endoplasmic reticulum (ER) stress and autophagy that drive the spatiotemporally coordinated emission of immunostimulatory damage-associated molecular patterns (DAMPs) and cytokines. First characterized experimentally by Guido Kroemer, Laurence Zitvogel, Noelia Casares, Michel Obeid, and colleagues between 2005 and 2007, ICD overturns the twentieth-century dichotomy that equated morphological apoptosis with immunological tolerance (silent efferocytosis) and necrosis with non-specific inflammation. Instead, when tumor cells are killed by true ICD inducers—such as anthracyclines (doxorubicin, epirubicin, mitoxantrone), oxaliplatin, bortezomib, photodynamic therapy (PDT), oncolytic viruses, or focal ionizing radiotherapy—they expose and release a triad of adjuvant DAMPs (surface calreticulin [CRT], extracellular ATP, and HMGB1 / Annexin A1) alongside Type I interferons. These signals recruit immature dendritic cells (DCs) into the tumor bed, promote phagocytic engulfment and cross-presentation of tumor-associated neoantigens on MHC class I molecules, and prime cytotoxic CD8+ T cells—converting the dying tumor into an in situ endogenous vaccine (Casares et al., 2005; Obeid et al., 2007; Kroemer et al., 2013; Galluzzi et al., 2017, 2020).

The Gold-Standard Vaccination Assay and Antigenicity vs. Adjuvanticity

For a dying cell to elicit an adaptive immune response in an immunocompetent host, two independent criteria must be met simultaneously (Galluzzi et al., 2017, 2020):

  1. Antigenicity: The dying cell must express non-self or mutated epitopes not covered by central thymic tolerance—such as viral or bacterial proteins in infected cells, or somatic tumor neoantigens and cancer–testis antigens in malignant cells.
  2. Adjuvanticity (DAMP Emission): Because antigen presentation in the absence of co-stimulation induces T-cell anergy or peripheral tolerance, the dying cell must emit endogenous danger signals (DAMPs) that engage pattern-recognition receptors (PRRs) on conventional type 1 dendritic cells (cDC1s, CD103+ / XCR1+ / BATF3-dependent DCs) to drive co-stimulatory molecule upregulation (CD80, CD86, CD40) and IL-12 / IL-1β secretion.

According to the Consensus Guidelines for the Detection of Immunogenic Cell Death (Kepp et al., 2014; Galluzzi et al., 2020), the definitive proof that a cytotoxic agent induces bona fide ICD is the in vivo prophylactic vaccination assay in syngeneic, immunocompetent mice:

  • Tumor cells (e.g., CT26 colon carcinoma or MCA205 fibrosarcoma) are treated in vitro with the candidate agent until they commit to death, washed free of the drug, and injected subcutaneously into the left flank of immunocompetent syngeneic mice without any exogenous adjuvant.
  • One to two weeks later, the mice are challenged in the contralateral (right) flank with live, untreated tumor cells of the identical clone.
  • Non-Immunogenic Death (e.g., Cisplatin or Mitomycin C): Although cisplatin kills tumor cells via caspase-3-dependent apoptosis in vitro, it fails to trigger ER stress / PERK phosphorylation or surface calreticulin translocation; vaccinated mice fail to mount protective immunity and develop tumors at the challenge site like naive controls (Martins et al., 2011).
  • Immunogenic Cell Death (e.g., Doxorubicin, Mitoxantrone, or Oxaliplatin): In 70% to 100% of immunocompetent mice, the dying-cell vaccine prevents tumor growth upon live-cell rechallenge—a protective effect that is abolished in athymic nu/nu mice, Rag2−/− mice, or mice depleted of CD8+ T cells or interferon-γ (IFN-γ) (Casares et al., 2005; Obeid et al., 2007).

The Spatiotemporal DAMP Cascade: "Find-Me," "Eat-Me," and Maturation Signals

ICD relies on an ordered sequence of premortem stress pathways and postmortem membrane permeabilization events that emit six hallmark signals (Kroemer et al., 2013; Galluzzi et al., 2020):

DAMP / Danger SignalPremortem Stress & Trafficking MechanismCognate Receptor on Dendritic Cells / Myeloid CellsImmunological Function in the ICD Cascade
1. Surface Calreticulin (ecto-CRT) & ERp57Premortem Unfolded Protein Response (UPR): Phosphorylation of eIF2α on Ser51 by PERK (and inhibition of PP1/GADD34) triggers caspase-8 cleavage of BAP31, BAX/BAK activation, and anterograde SNARE-dependent exocytosis of lumenal ER chaperone calreticulin (CRT) to the outer leaflet of the plasma membrane before phosphatidylserine exposure.CD91 (LRP1, Low-Density Lipoprotein Receptor-Related Protein 1) on immature cDC1s and macrophagesThe Obligate "Eat-Me" Signal: Overrides the antiphagocytic "don't-eat-me" signal CD47–SIRPα, directing engulfment of dying tumor fragments specifically into cross-presenting dendritic cells rather than tolerogenic macrophages (Obeid et al., 2007).
2. Extracellular ATP (Adenosine Triphosphate)Premortem Autophagy & Pannexin-1 Channels: Premortem autophagy preserves intracellular ATP pools inside autolysosomes; during early apoptosis, caspase-3/7 cleaves the C-terminal autoinhibitory tail of pannexin-1 (PANX1) hemichannels, releasing ATP into the extracellular space.P2RY2 (metabotropic purinergic receptor) and P2RX7 (ionotropic purinergic receptor)Dual "Find-Me" & Inflammasome Signal: At nanomolar levels, ATP binds P2RY2 to chemoattract monocytes and DCs into the tumor bed; at micromolar levels, ATP gates P2RX7 (K+ efflux), activating the NLRP3 inflammasome and caspase-1 to secrete IL-1β (IL-1R1-dependent CD8+ T-cell polarization) (Ghiringhelli et al., 2009; Michaud et al., 2011).
3. Annexin A1 (ANXA1)Released from the cytosol during late-stage plasma membrane permeabilization.FPR1 (Formyl Peptide Receptor 1) on dendritic cellsChemotactic Homing & Synapse Stabilization: Guides migrating DCs into direct physical contact with dying cancer cells to form stable phagocytic synapses; loss-of-function FPR1 polymorphisms (rs867228) abolish anthracycline chemotherapy benefit in breast and colorectal cancer patients (Vacchelli et al., 2015).
4. HMGB1 (High-Mobility Group Box 1)Non-histone nuclear chromatin-binding protein that translocates from the nucleus to the cytoplasm and is released extracellularly upon secondary plasma membrane permeabilization in its disulfide redox state.TLR4 (Toll-Like Receptor 4) and RAGE on dendritic cellsAntigen Processing & Cross-Presentation Signal: Signaling via TLR4–MyD88 inhibits phagolysosomal fusion and rapid proteolytic degradation of engulfed tumor cargo inside DCs, routing intact neoantigen peptides into the MHC class I cross-presentation pathway (Apetoh et al., 2007).
5. Type I Interferons (IFN-α/β) & CXCL10Cytosolic double-stranded DNA (micronuclei / mtDNA) activates cGAS–STING, while endogenous retroviral dsRNA activates TLR3 or RIG-I/MDA5.IFNAR1 / IFNAR2 (autocrine on tumor cells and paracrine on DCs/T cells)Autocrine/Paracrine Chemokine Loop: Induces secretion of CXCL10 (IP-10), recruiting CXCR3+ effector CD8+ cytotoxic T lymphocytes and NK cells into the tumor microenvironment (Sistigu et al., 2014).
6. Surface Heat-Shock Proteins (HSP70, HSP90)Translocated from cytosol/ER to the plasma membrane and released on exosomes during proteotoxic and oxidative ER stress.CD91 (LRP1), TLR2/TLR4, and LOX-1Chaperone tumor antigenic peptides directly into the DC cross-presentation machinery and stimulate DC maturation (Spisek et al., 2007).

Type I vs. Type II ICD Inducers and Non-Apoptotic Regulated Death Pathways

Pharmacological and physical ICD inducers are classified into two mechanistic categories based on how they elicit endoplasmic reticulum stress (Krysko et al., 2012; Galluzzi et al., 2017):

  • Type I ICD Inducers (Collateral ER Stress): Agents whose primary pharmacological target lies outside the ER (such as nuclear DNA or microtubules), but which trigger ER stress and eIF2α phosphorylation via secondary signaling cascades. Examples include anthracyclines (doxorubicin, epirubicin, idarubicin), mitoxantrone, oxaliplatin (which unlike cisplatin induces nucleolar ribosome biogenesis stress and eIF2α phosphorylation, Bruno et al., 2017), cyclophosphamide, bortezomib (26S proteasome inhibitor used in multiple myeloma), cardiac glycosides (digoxin, digitoxin), and ionizing radiation (which underpins the systemic abscopal effect when combined with anti-CTLA-4 or anti-PD-1 immune checkpoint blockade).
  • Type II ICD Inducers (Focused ER Oxidative Stress): Agents that selectively localize to the endoplasmic reticulum and generate reactive oxygen species (ROS) directly inside the ER lumen, triggering rapid, high-amplitude PERK-dependent ecto-CRT exposure and ATP secretion. The archetypes are hypericin-based photodynamic therapy (Hyp-PDT) and oncolytic viruses (such as talimogene laherparepvec [T-VEC] and Newcastle disease virus).

Beyond caspase-dependent immunogenic apoptosis, regulated lytic cell death modalities—including RIPK1/RIPK3/MLKL-driven necroptosis, gasdermin-mediated pyroptosis (such as chemotherapy-induced caspase-3 cleavage of gasdermin E [GSDME]), and lipid-peroxidation-driven ferroptosis—also release large quantities of HMGB1, ATP, and inflammatory cytokines, acting as potent non-apoptotic vectors of immunogenic cell death in cancer immunotherapy (Wang et al., 2017; Galluzzi et al., 2020).

Clinical Translation and Host Genetic Loss-of-Function Biomarkers

Translational oncology studies have confirmed that the therapeutic efficacy of standard-of-care chemotherapies and radiotherapies in humans depends on an intact host ICD signaling axis:

  • Host TLR4, P2RX7, and FPR1 Polymorphisms: Breast cancer, colorectal cancer, and esophageal carcinoma patients carrying loss-of-function single-nucleotide polymorphisms in TLR4 (Asp299Gly, rs4986790), P2RX7 (Glu496Ala, rs3751143), or FPR1 (Glu346Ala, rs867228) exhibit normal tumor shrinkage rates immediately after anthracycline or oxaliplatin chemotherapy, but suffer significantly shorter metastasis-free and overall survival because their dendritic cells fail to sense HMGB1, ATP, or Annexin A1 emitted by dying tumor cells (Apetoh et al., 2007; Ghiringhelli et al., 2009; Vacchelli et al., 2015).
  • Chemo-Immunotherapy Synergy: Combining ICD-inducing chemotherapy (such as oxaliplatin or nanoparticle-bound paclitaxel/anthracyclines) or stereotactic body radiotherapy (SBRT) with PD-1/PD-L1 or CTLA-4 checkpoint inhibitors converts immunologically "cold" (T-cell-excluded) tumors into "hot" (T-cell-infiltrated) tumors, forming the clinical backbone of modern first-line combination regimens across triple-negative breast, non-small-cell lung, gastric, and gastroesophageal cancers (Voorwerk et al., 2019; Galluzzi et al., 2020).

References

  1. Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., Coutant, F., Métivier, D., Pichard, E., Aucouturier, P., Pierron, G., Garrido, C., Zitvogel, L., & Kroemer, G. (2005). Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. Journal of Experimental Medicine, 202(12), 1691–1701. https://doi.org/10.1084/jem.20050915
  2. Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., Métivier, D., Larochette, N., van Endert, P., Ciccosanti, F., Piacentini, M., Zitvogel, L., & Kroemer, G. (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Medicine, 13(1), 54–61. https://doi.org/10.1038/nm1523
  3. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., Yang, H., Amigorena, S., Ryffel, B., Barrat, F. J., Saftig, P., Levi, F., Lidereau, R., Nogues, C., Mira, J.-P., Chompret, A., Joulin, V., Clavel-Chapelon, F., Bourhis, J., André, F., Delaloge, S., Tursz, T., Kroemer, G., & Zitvogel, L. (2007). Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine, 13(9), 1050–1059. https://doi.org/10.1038/nm1622
  4. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., Perfettini, J.-L., Schlemmer, F., Tasdemir, E., Uhl, M., Génin, P., Civas, A., Ryffel, B., Kanellopoulos, J., Tschopp, J., André, F., Lidereau, R., McLaughlin, N. M., Haynes, N. M., Smyth, M. J., Kroemer, G., & Zitvogel, L. (2009). Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors. Nature Medicine, 15(10), 1170–1178. https://doi.org/10.1038/nm.2028
  5. Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013). Immunogenic cell death in cancer therapy. Annual Review of Immunology, 31, 51–72. https://doi.org/10.1146/annurev-immunol-032712-100008
  6. Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017). Immunogenic cell death in cancer and infectious disease. Nature Reviews Immunology, 17(2), 97–111. https://doi.org/10.1038/nri.2016.107
  7. Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., Draganov, D., Edelson, R. L., Formenti, S. C., Fucikova, J., Gabriele, L., Gaipl, U. S., Gameiro, S. R., Garg, A. D., Golden, E., … Marincola, F. M. (2020). Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. Journal for ImmunoTherapy of Cancer, 8(1), e000337. https://doi.org/10.1136/jitc-2019-000337
🧬 Support Open Science
Explore interactive science games on LowKey Games or browse scientific apparel & accessories in the CRV Science Shop.
💡 Spot an inaccuracy or have primary literature to expand this article?
Submit a citation or revision note using your shared CRV Science / LowKey Games profile ID.
Suggest Revision